Image source: Getty Images
There’s a FTSE stock in my portfolio that looks like it’s just done a couple of rounds with Mike Tyson (the young version). It’s down 26% in just 10 days and now trades for 22p.
The stock is hVIVO (LSE: HVO), a small-cap from the FTSE AIM 100 index. There’s been no significant news published during this time, other than Octopus Investments (the firm’s largest shareholder) increasing its stake from 12.32% to 13.32%. That’s a positive sign.
So what’s going on here? And is this a chance for me to buy more shares? Let’s dig in.
Ask questions later
hVIVO conducts human challenge trials for biopharma companies, which involves exposing healthy volunteers to pathogens under controlled conditions. These provide quicker data, cut costs, and can speed up the clinical trial process.
Now, exact figures aren’t publicly disclosed, but it’s safe to assume that a…
